Analysts cut Savara after lead asset misses primary endpoint

Landenburg Thalmann downgraded Savara (NASDAQ:SVRA) to “neutral” from “buy” and slashed its price target to $3 from $21 after lead asset, Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, failed to reach its primary endpoint in a Phase 3 trial for the treatment of autoimmune pulmonary alveolar proteinosis.

Read More
Stephen Kilmer
HCW ups Sesen Bio to buy; PT to $3

H.C. Wainwright upgraded Sesen Bio (NASDAQ:SESN) to “buy” from “neutral” and raised its price target to $3 from $1 after the company had a successful Type B pre-biologics license application (BLA) meeting with FDA for its lead product, Vicinium…

Read More
Stephen Kilmer